Assembling evidence grade
Loading
Independent evidence before payment.
Synthetic tetrapeptide · also: Epithalon, AEDG peptide
Epitalon carries an Evidence Grade of C (High confidence). The strongest published evidence catalogued is human (other).
Grade C rule: At least one other human study.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
Epitalon is a synthetic tetrapeptide studied primarily in older Eastern-European literature for telomere and pineal-related endpoints.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 2 human studies, but no randomised trial — the strongest test has not been done. Effects seen in smaller studies often do not hold up.
Strongest: randomised or pooled human trials.
none catalogued
Observational, open-label or small human studies.
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025.
[AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging.]. Advances in gerontology = Uspekhi gerontologii, 2020.
Preclinical animal models — not a human outcome.
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 2022.
Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In vivo (Athens, Greece), 2006.
Cell / tissue studies — not a human outcome.
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem cell reviews and reports, 2025.
Short Peptides Protect Oral Stem Cells from Ageing. Stem cell reviews and reports, 2020.
Proposed mechanism — hypothesis, not evidence of effect.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging, 2026.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences, 2025.
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland), 2020.
[Aging of the pineal gland]. Advances in gerontology = Uspekhi gerontologii, 2002.
Peptides and Ageing. Neuro endocrinology letters, 2002.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Independent replication is limited; much of the literature is methodologically weak. Longevity claims are not established.
Not an approved medicine in major markets. Sold only as a “research chemical”, with no established safe consumer use, dose or supply standard.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Not approved for human use.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.